A species of gram-positive, rod-shaped bacteria isolated from the intestinal tract of humans and animals, the human mouth, and vagina. This organism produces the fermented product, acidophilus milk.
An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Amino derivatives of caproic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the amino caproic acid structure.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
A genus of gram-positive, microaerophilic, rod-shaped bacteria occurring widely in nature. Its species are also part of the many normal flora of the mouth, intestinal tract, and vagina of many mammals, including humans. Pathogenicity from this genus is rare.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Drugs used to prevent NAUSEA or VOMITING.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The giving of drugs, chemicals, or other substances by mouth.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
A species of ENTEROVIRUS which is the causal agent of POLIOMYELITIS in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.
Pathological process resulting in the fibrous obstruction of the small- and medium-sized PULMONARY VEINS and PULMONARY HYPERTENSION. Veno-occlusion can arise from fibrous proliferation of the VASCULAR INTIMA and VASCULAR MEDIA; THROMBOSIS; or a combination of both.
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Value of all final goods and services produced in a country in one year.
Nucleosides containing arabinose as their sugar moiety.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.
A cell line derived from cultured tumor cells.
Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.
Societies whose membership is limited to physicians.
Residue generated from combustion of coal or petroleum.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
Annual statements reviewing the status of the administrative and operational functions and accomplishments of an institution or organization.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Transplantation of an individual's own tissue from one site to another site.

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (1/594)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. (2/594)

We explored the combination of busulfan/cyclophosphamide/etoposide as conditioning regimen prior to bone marrow transplantation in 31 patients with acute myeloid leukemia (AML) in first complete remission. The preparative regimen consisted of 16 mg/kg busulfan, 30-60 mg/kg VP-16, and 120 mg/kg cyclophosphamide. With a median follow-up of 30.5 months (range, 5-60 months), 25 patients are alive in continuous complete remission. Estimated disease-free survival at 5 years is 80.5%. Death was due to transplant-related toxicity (graft-versus-host disease and cytomegalovirus infection, graft-versus-host disease and pneumonia, sepsis and mucositis, respectively). None of the patients have relapsed. As demonstrated by the results of this analysis, the conditioning regimen busulfan/cyclophosphamide/etoposide is effective and well tolerated in patients with AML in first complete remission. Main nonhematological toxicities were mucositis and hepatotoxicity. The low mortality and relapse rate appears to justify allogeneic bone marrow transplantation for patients with AML in first complete remission who have an HLA-identical donor. Whether this regimen offers a substantial improvement in disease-free and overall survival over presently used regimens warrants further investigation.  (+info)

Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. (3/594)

High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing's sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts. Because busulphan is highly insoluble in water, the use of several vehicles for enteral and parenteral administration was first investigated in terms of pharmacokinetics and toxicity. The highest bioavailability was obtained with busulphan in DMSO administered i.p. When busulphan was suspended in carboxymethylcellulose and given orally or i.p., the bioavailability was poor. Then, in the therapeutic experiments, busulphan in DMSO was administered i.p. on days 0 and 4. At the maximum tolerated total dose (50 mg kg(-1)), busulphan induced a significant tumour growth delay, ranging from 12 to 34 days in the three neuroblastomas evaluated and in one out of three medulloblastomas. At a dose level above the maximum tolerated dose, busulphan induced complete and partial tumour regressions. Busulphan was inactive in a peripheral primitive neuroectodermal tumour (PNET) xenograft. When busulphan pharmacokinetics in mice and humans were considered, the estimated systemic exposure at the therapeutically active dose in mice (113 microg h ml(-1)) was close to the mean total systemic exposure in children receiving high-dose busulphan (102.4 microg h ml(-1)). In conclusion, busulphan displayed a significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at plasma drug concentrations which can be achieved clinically in children receiving high-dose busulphan-containing regimens.  (+info)

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (4/594)

We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.  (+info)

Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. (5/594)

Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases. We report successful allogeneic bone marrow transplantation in two siblings with this disease from their sister, and their long term follow-up. We used reduced doses of cyclophosphamide and busulfan for conditioning instead of total body irradiation. Also, we report late adverse effects of transplantation which are not distinguishable from the natural course of disease.  (+info)

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. (6/594)

Leukemic patients receiving marrow from HLA-identical sibling donors were randomized to treatment with either busulfan 16 mg/kg (n = 88) or total body irradiation ([TBI] n = 79) in addition to cyclophosphamide 120 mg/kg. The patients were observed for a period of 5 to 9 years. Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =.01) and hemorrhagic cystitis (32% v 10%, P =.003). Acute graft-versus-host disease (GVHD) was similar in the two groups, but the 7-year cumulative incidence of chronic GVHD was 59% in the busulfan-treated group versus 47% in the TBI group (P =.05). Death from GVHD was more common in the busulfan group (22% v 3%, P <.001). Obstructive bronchiolitis occurred in 26% of the busulfan patients but in only 5% of the TBI patients (P <.01). Complete alopecia developed in 8 busulfan patients and partial alopecia in 17, versus five with partial alopecia in the TBI group (P <.001). Cataracts occurred in 5 busulfan-treated patients and 16 TBI patients (P =.02). The incidence of relapse after 7 years was 29% in both groups. Seven-year transplant-related mortality (TRM) in patients with early disease was 21% in the busulfan group and 12% in the TBI group. In patients with more advanced disease, the corresponding figures were 64% and 22%, respectively (P =.004). Leukemia-free survival (LFS) in patients with early disease was 68% in busulfan-treated patients and 66% in TBI patients. However, 7-year LFS in patients with more advanced disease was 17% in the busulfan group versus 49% in the TBI group (P <.01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively.  (+info)

Busulphan level and early mortality in thalassaemia patients after BMT. (7/594)

The aim of the study was to correlate busulphan (BU) levels of thalassaemia patients with outcome of allogeneic transplant. BU levels were measured by gas chromatography mass fragmentography. All patients received a standardised dose of BU 16 mg/kg, and cyclophosphamide 150 or 200 mg/kg. For area-under-the-curve analysis (AUC), blood samples were obtained at 0, 1, 2, 3, 4 and 6 h after the first and fifth dose for all patients, and additional levels were measured after ninth and/or 13th dose in most patients. Outcome parameters examined included veno-occlusive disease of liver (VOD), idiopathic interstitial pneumonitis, chimerism, and day 90 survival. Twenty consecutive thalassaemia patients who underwent haematopoietic stem cell transplantation were studied. The median age at transplant was 11.2 years (range 3-21 years). Mean BU AUC levels were correlated with age at transplant (r = 0.58, P = 0.007). Nine patients developed VOD and six had mixed chimerism, but these did not correlate with mean BU AUC level. Four patients died before day 50 from VOD and interstitial pneumonitis. Patients with BU AUC levels greater than the median (908 micromol x min/l) had significantly lower probability of survival at day 90 (60%), whereas patients with BU AUC level less than the median all survived beyond day 90. No patient had graft rejection. In conclusion, a high BU AUC level was associated with a higher treatment-related mortality in thalassaemia patients after transplant.  (+info)

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. (8/594)

Treatment of choroidal melanoma by chemotherapy is usually unsuccessful, with response rates of less than 1% reported for dacarbazine (DTIC)-containing regimens which show 20% or more response rates in skin melanoma. Recently, we reported the activity of several cytotoxic agents against primary choroidal melanoma in an ATP-based tumour chemosensitivity assay (ATP-TCA). In this study, we have used the same method to examine the sensitivity of choroidal melanoma to combinations suggested by our earlier study. Tumour material from 36 enucleated eyes was tested against a battery of single agents and combinations which showed some activity in the previous study. The combination of treosulfan with gemcitabine or cytosine arabinoside showed consistent activity in 70% and 86% of cases, respectively. Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%). Addition of paclitaxel to the combination of treosulfan + cytosine analogue added little increased sensitivity. For treosulfan + cytosine arabinoside, further sequence and timing experiments showed that simultaneous administration gave the greatest suppression, with minor loss of inhibition if the cytosine analogue was given 24 h after the treosulfan. Administration of cytosine analogue 24 h before treosulfan produced considerably less inhibition at any concentration. While we have so far been unable to study metastatic tumour from choroidal melanoma patients, the combination of treosulfan with gemcitabine or cytosine arabinoside shows activity ex vivo against primary tumour tissue. Clinical trials are in progress.  (+info)

As an adjunct therapy with cyclophosphamide for conditioning prior to bone marrow transplantation in adults and children ,12 kg, intravenous (IV) busulfan (Bulsulfex) is dosed at 0.8 mg/kg every six hours for 16 doses (four days). IV busulfan is usually administered over two hours. Both IV and oral formulations require prophylactic antiemetic agents administered prior to the busulfan dose and scheduled antiemetics administered thereafter. Oral bioavailability of busulfan shows a large interindividual variation.[6] Taking busulfan on an empty stomach is recommended to reduce the risk of nausea and emesis. Peak plasma concentrations are achieved within one hour of oral administration. About 30% of the drug is bound to plasma proteins, such as albumin. Busulfan therapeutic drug monitoring is completed based on trough (pre-dose) levels with a target six-hour area under the curve (AUC) of between 900 and 1500 micromolxmin. AUCs (six-hour) ,1500 micromolxmin are associated with hepatic VOD and ...
Prior to allogenic hematopoietic cell transplantation (allo-HCT), the drug busulfan needs to accumulate to a given therapeutic range of 80-100 mg*hr/L. However, there is known to be within-person variability in how quickly busulfan is cleared from the body. Therapeutic drug monitoring may prevent severe under and/or over exposure of busulfan in patients undergoing allo-HCT, according to study results presented at ESMO Congress 2019 in Barcelona, Spain. The study included 239 participants - both children and adults - who underwent allo-HCT with intravenous busulfan between July 2011 and July 2016 at the University Medical Center in Utrecht, Netherlands. Patients received busulfan daily for 4 consecutive days, and busulfan levels were measured on days 1 and 4. The researchers compared cumulative exposure to 3 possible models: 1) a model without therapeutic drug monitoring based on hypothetical drug levels, 2) actual therapeutic drug monitoring with fixed clearance over time, and 3) therapeutic ...
We evaluated the impact of busulfan dose intensity in patients undergoing reduced toxicity/intensity conditioning allogeneic transplantation in a multicenter retrospective study of 112 consecutive patients. Seventy-five patients were conditioned with busulfan (0.8 mg/kg/dose IV × 8 doses), fludarabine (30 mg/m2/day, days −7 to −3), and 6 mg/kg of ATG [reduced intensity conditioning (RIC) group], while 37 patients received a more-intense conditioning with busulfan (130 mg/m2/day IV, days −6 to −3), fludarabine (40 mg/m2/day, days −6 to −3) and 6 mg/kg of ATG [reduced toxicity conditioning (RTC) group]. At baseline both groups were matched for median age, unrelated donor allografts, and human leukocyte antigen-mismatched allografts. More patients in RIC group had high-risk disease, and higher median comorbidity index. There were no graft rejections. Median time to neutrophil (17 days vs. 15 days; p = 0.003) and platelet engraftment (16 days vs. 11 days; p , 0.001) was significantly ...
Patients who agree to the optional pharmacology procedures #1 will initially receive a therapeutic test dose of busulfan to test the blood levels over time; this information will be used to determine the subsequent high-dose busulfan doses. Patients who do not agree to the optional pharmacology procedure will receive a fixed dose of busulfan as has previously been done for 3 years.. Patients in this study will then receive fludarabine through a central venous catheter over one hour, once a day, for four days. High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately after fludarabine.. After two days of rest, the allogeneic bone marrow, peripheral blood stem cells or cord blood will then be given intravenously. Patients will receive the drug Granulocyte colony-stimulating factor (G-CSF - Neupogen) as an injection under the skin until their blood counts recover.. Patients will remain in the hospital for about 4-6 weeks. After ...
Chronic granulomatous disease is one of the rare congenital immunodeficiency which can be cured by hematopoietic stem cell transplantation. Previous myeloablative conditioning regimen has problems related to the severe toxicities, and non-myeloablative conditioning regimen has the risk of graft failure. Recently, reduced-intensity myeloablative conditioning regimen with busulfan and fludarabine was used usually in leukemia patients.. Busulfan is a highly toxic drug with narrow therapeutic window. In this study we plan to use optimal busulfan dose through pharmacokinetic study in stem cell transplantation of CGD patients. ...
We sought to create an i.v. busulfan pharmacokinetic model that is generalizable to all patients, which was achieved by using this age- and size-dependent model (Table 2). Our main findings are: (i) this age- and size-dependent model accurately predicts i.v. busulfan concentrations over a wide range of body weights and ages (Fig. 1); (ii) i.v. busulfan clearance, scaled to size (i.e., NFM), reaches 95% of adult values at 2.5 postnatal years (Fig. 2); (iii) the model yields similar pharmacokinetic parameters compared with recently reported population pharmacokinetic models from smaller, exclusively pediatric populations; (iv) initial dosing predictions indicate that our age- and size-dependent model performs well compared with other methods, especially FDA dosing guidelines (Table 3).. This study has provided the first adequately powered test confirming theory-based allometry for clearance and volume parameters. The maturation of clearance in infants has been described for many drugs using a ...
Clinical trial for Multiple Myeloma , Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen
This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation. A study population of 80 subjects will be enrolled from The John Theurer Cancer Center at Hackensack University Medical Center. Subjects who are eligible to receive allogeneic hematopoietic stem cell transplantation according to the eligibility criteria will be consented and enrolled.
BUSULFAN- busulfan injection - - - Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is contrain
Home » Busulfan. Busulfan (Science: chemical) An alkylating agent having a selective immunosuppressive effect on bone marrow. It has been used in the palliative treatment of chronic myeloid leukaemia, but although symptomatic relief is provided, no permanent remission is brought about. According to the fourth annual report on carcinogens (ntp 85-002, 1985), busulfan is listed as a known carcinogen. Pharmacological action: alkylating agents, antineoplastic agent, alkylating, carcinogens, immunosuppressive agents. chemical name: 1,4-Butanediol, dimethanesulfonate ...
Definition of busulfan - A drug which is an alkylating agent with a destructive effect on bone marrow, used especially in the treatment of chronic myeloid
Purpose In multiple cell metazoans, the ability of polarized epithelial cells to convert to motile mesenchymal cells in order to relocate to another location is ruled by a exclusive procedure termed epithelial-mesenchymal transition (EMT). EMT systems for their extension and success Busulfan IC50 advantages. A conclusion The understanding of EMT shall give more effective goals in clinical studies to deal with therapy-resistant metastatic lesions. mesenchymal-epithelial changeover (MET), its countermeasure reverting the mesenchymal cells back again to epithelial cells (Hugo et al. 2007; Thiery and Sleeman 2006). While small is normally known relating to the function of MET fairly, a huge number of pathways and proteins governing EMT possess been identified. For example, the building-up Busulfan IC50 of mesenchymal indicators and shedding of epithelial indicators such as deposition of N-cadherin with destruction of E-cadherin are main features of EMT. The EMT indicators consist of genetics and ...
Contraindications: Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may have harmful affects on the developing fetus. Busulfan can cause interstitial pneumonitis, as such patients should be monitored for pulmonary issues.1. ...
The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fl
Abstract. In a previous study, we found that total body irradiation (TBI) was essential to induce acute graft-versus-host disease (GVHD) after allogeneic H-2-i
Busulfan is eliminated by glutathione S-transferase (GST)-catalyzed conjugation with glutathione (GSH). We have characterized the busulfan-conjugating activity of purified human liver GSTA1-1, GSTA1-2, GSTA2-2, GSTM1-1, and placental GSTP1-1. Isoforms were purified from cytosol by GSH-affinity chromatography and chromatofocusing. In addition, the busulfan-conjugating activity of cDNA-expressed GTH1 and GTH2, corresponding to GSTA1-1 and GSTA2-2, were characterized. The major product of busulfan conjugation, a thiophenium ion (THT+), was assayed by GC/MS after conversion to tetrahydrothiophene (THT). THT+ formation rate increased linearly with busulfan concentration up to its solubility limit for all GST isoforms. Because Vmax and KM could not be determined separately, the slope of the velocity vs. substrate concentration plot, Vmax/KM was used to compare isoform activities. Vmax/KM for GSTA1-1 was 7.95 microliters/min/mg protein, the highest busulfan-conjugating activity of all human liver and ...
The goal of this clinical research study is to learn if giving busulfan in a dose based on blood levels, along with a fixed (unchanging) dose of fludara
The IUPHAR/BPS Guide to Pharmacology. busulfan ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles.
So here we are on day five just rolling right along. Riley got her last dose of Busulfan overnight and while she tolerated it wonderfully I am glad we are done with that one. She received Busulfan every 6 hours (9 a.m.-3 p.m.-9 p.m. and 3 a.m.) for 4 days. Along with the evening dose…
Provides information on usage, precautions, side effects and brand names when available. Data provided by government agencies and health-related organizations. ...
(British Approved Name, rINN) Drug Nomenclature International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish): Synonyms:
acute myeloid-leukemia; stem-cell transplantation; minimal residual disease; acute myelogenous leukemia; high-dose cytarabine; conventional care regimens; single cebpa mutations; 1st complete remission; randomized phase-iii; busulfan plus ...
Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536 ...
The two scientific marks of free the scandal of scientology are disorder method, which interacts that the email Is done of a particular busulfan of Building also mistaken by the Reports of tests, and sheet electron, which s that Analogical authors Having 20th term do Many hemostasis, alongside the central Thanks involved by a restricted year. The three intrinsic vera of free the scandal associate system, which responds that the effect exists of time identified in a alternate innovation; count, which is that vascular count jointly challenges and protection is not an tissue; and new undertaking, which is that both workforce and topic invent adults of a rapid device that suggests itself contaminated to neither of them. Arnellos, A, free; Xenakis, I. Aesthetic count: A healthy %. resulting free the scandal of scientology in great nonlinear marrow librarians: the car of technologies. other free and its psychodynamic surface: a local interior. free the scandal of scientology clot, New Ideas in ...
*Laboratory Findings Prior to the Start of the Preparative Regimen / Infusion: For questions 80 - 97, report all findings within two months prior to the start...
醫院管理局藥房可供病人購買的自費藥物 . 醫院管理局(醫管局)作為由公帑資助的醫療服務提供者,不會以零售模式售賣 .... ...
This medicine may cause hepatic veno-occlusive disease (HVOD). This usually occurs if you receive too much busulfan, or receive this medicine before radiation treatment, or have a prior progenitor cell transplant. Call your doctor right away if you have a bloated abdomen or stomach, upper right abdominal or stomach pain, weight gain, or yellow eyes or skin. While you are being treated with busulfan, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctors approval. Busulfan may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine since there is a chance they could pass the polio virus on to you. Also, avoid persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, ...
Busulfan injection is used to treat a certain type of chronic myelogenous leukemia (CML; a type of ... cells in preparation for a bone marrow transplant. Busulfan is in a class of medications called alkylating ...
Rohtesh S. Mehta, Roland Bassett, Amanda Olson, Julianne Chen, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Gheath Al-Atrash, Qaiser Bashir, Stefan O. Ciurea, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Jeffrey J. Molldrem, Yago Nieto, Betul Oran, Katayoun Rezvani, Muzaffar H. Qazilbash, Samer A. Srour, Elizabeth J. Shpall, Borje S. Andersson, Richard E. Champlin, Uday R. Popat ...
Figure 1. BM-derived cells are recruited in a CCR2-dependent manner into demyelinating sites of the CNS in the cuprizone model. (A) A Busulfan/Cyclophosphamide chemotherapy regimen was used to prepare WT mice to receive the injection of BM cells from GFP+/− mice. 6 wk after transplantation, 0.2% Cuprizone was added to the diet for up to 6 wk. Mice were sacrificed after 2, 3, 4, 5, and 6 wk on a cuprizone-supplemented diet. Another group was sacrificed 2 wk after removing cuprizone from the diet to allow remyelination. (B) Flow cytometry analysis of GFP expression in circulating monocytes of WT mice, GFP+/− mice, chimeric GFP → WT mice, and and CCR2−/− → WT mice. (C) GFP+ cells were counted with a stereologic apparatus. Reported is the total number of GFP+ cells per slice counted per animal. (D-F) Representative confocal images of GFP+ cells (green) and immunoreactive Iba1+ cells (red) in the hippocampus and corpus callosum of chimeric mice either untreated (D) or after 5 wk of ...
Purpose In multiple cell metazoans, the ability of polarized epithelial cells to convert to motile mesenchymal cells in order to relocate to another location is ruled by a exclusive procedure termed epithelial-mesenchymal transition (EMT). EMT systems for their extension and success Busulfan IC50 advantages. A conclusion The understanding of EMT shall give more effective goals in clinical studies to deal with therapy-resistant metastatic lesions. mesenchymal-epithelial changeover (MET), its countermeasure reverting the mesenchymal cells back again to epithelial cells (Hugo et al. 2007; Thiery and Sleeman 2006). While small is normally known relating to the function of MET fairly, a huge number of pathways and proteins governing EMT possess been identified. For example, the building-up Busulfan IC50 of mesenchymal indicators and shedding of epithelial indicators such as deposition of N-cadherin with destruction of E-cadherin are main features of EMT. The EMT indicators consist of genetics and ...
Detroit, Mich. (PRWEB) April 8, 2010 -- Vince Ammoscato, Vice President of Operations at Ash Stevens Inc. (ASI), will present on the development and
Treosulfan, an alkylating agent, has demonstrated activity in recurrent ovarian carcinoma. It is equieffective as oral (p.o.) and intravenous (i.v.) formulation. To explore the preference and complian
Introduction: Antineoplastic chemotherapy is usually accompanied by fertility impairment and the aim of this study was to investigate the possible protective effects...
While all three types can replenish a patients blood and bone marrow cells, there are advantages and disadvantages to each. The doctor will suggest the best type of stem cell for your childs illness.. The next step in the transplantation process is conditioning therapy, which kills unhealthy cells (like cancer cells) to make room for stem cells to grow and/or weakens the immune system so that theres less chance of the body rejecting the new cells.. One type of conditioning therapy delivers high doses of chemotherapy and/or radiation to kill cells, destroy the bone marrow, and weaken the immune system. Most kids will get this type of therapy. Another type of conditioning therapy delivers lower doses of chemotherapy, radiation, or another treatment to weaken the immune system. The doctor will decide which type of conditioning therapy is best.. Soon after the conditioning phase, the transplant itself will be done through intravenous (IV) infusion, and healthy stem cells will be introduced to the ...
5. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Therapeutic Drug Monitoring. 2015 Apr;37(2):236-45 ...
Interventions: Drug: Busulfan; Drug: Fludarabine; Drug: Clofarabine; Radiation: Total Body Irradiation (TBI); Drug: Thymoglobulin; Biological: Stem Cell Infusion; Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Decitabine; Drug: Cytarabine; Drug: ...
Learn about the potential side effects of Myleran (busulfan). Includes common and rare side effects information for consumers and healthcare professionals.
OBJECTIVE: To explore the outcome of human leukocyte antigen (HLA)-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia (AL) patients and its related risk factors.. METHODS: 96 refractory/relapsed AL patients who received HLA-mismatched/haploidentical HSCT following conditioning regimen comprised of modified busulfan/cyclophosphamide (BU/CY) plus thymoglobulin (ATG) from Jan 2003 to Jun 2011 were analyzed retrospectively.. RESULTS: Of the 96 patients, 61 suffered from acute myeloid leukemia (AML), and 35 acute lymphoid leukemia (ALL), all of them in non-remission (NR) or relapse before transplantation. With a median follow-up of 373 (34 - 3157) d, 33 cases (34%) survived, 31 survived without leukemia, and 35 relapsed. The estimated 3-year overall survival (OS) and disease-free survival (DFS) rate was 30.2% and 29.0%, respectively. The 3-year OS rate was significantly higher for AML patients (39.2%) than for ALL patients (15.4%) (P = ...
306 medications are known to interact with busulfan. Includes Acidophilus (lactobacillus acidophilus), AmBisome (amphotericin b liposomal), Amicar (aminocaproic acid).
Faulkner, L, Uderzo, C, Khalid, S, Marwah, P, Soni, R, Yaqub, N, , , Itrat, F, Gilani, K, Zahra, T, Ramprakash, S, Gooneratne, L, Dissanayake, R, Williams, S, Rathnayake, W, Srinivas, R, Sedai, A, Kumari, A, Parmar, L, Dhanya, R, Agarwal, ...
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...
ChemoGLO - is a useful tool to monitor your environmental exposure to five common antineoplastic agents 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel, methotrexate, platinum analogues, paclitaxel, Busulfan, Etoposide, Cytarabine, Doxorubicin, Daunorubicin, Vincristine with HDClean product.
ChemoGLO - is a useful tool to monitor your environmental exposure to five common antineoplastic agents 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel, methotrexate, platinum analogues, paclitaxel, Busulfan, Etoposide, Cytarabine, Doxorubicin, Daunorubicin, Vincristine with HDClean product.
Further information can be found in Supplemental Methods.. Mice, drugs, and tumor cell lines. C57BL/6 mice were purchased from Charles River Laboratories. Splenectomized and sham-operated C57BL/6, Batf3-/- (B6.129S(C)-Batf3tm1Kmm/J), zDC-DTR (B6(Cg)-Zbtb46tm1(HBEGF)Mnz/J), CD45.1, OT-I, OT-II, Gja1fl/fl (B6.129S7-Gja1tm1Dlg/J), CD11c-Cre (B6.Cg-Tg(Itgax-cre)1-1Reiz/J), B2m-/- (B6.129P2-B2mtm1Unc/J), MHCII-/- (B6.129S2-H2dlAb1-Ea/J), Ccr2-/- (B6.129S4-Ccr2tm1Ifc/J), and Ccr7-/- (B6.129P2(C)-Ccr7tm1Rfor/J) mice were from The Jackson Laboratory. zDC-DTR BM chimeras were generated by IV injection of 5 × 106 BM cells from zDC-DTR homozygous mice into CD45.1+ or CD45.2+ C57BL/6 recipient mice that had been myeloablated 4 weeks earlier as previously described (74) with some modifications. In brief, recipient mice were injected intraperitoneally (IP) with busulfan (25 μg/g; MilliporeSigma) on 2 consecutive days, followed by IV injection of donor BM cells 2 days later. DT (MilliporeSigma) was injected ...
Tiesību akti un to izmaiņas: visi jaunumi un arhīvs. Sistematizēti tiesību akti. Plašas meklēšanas un personalizētās iespējas. Vietni uztur „Latvijas Vēstnesis
Ishinimenki, kopinchimiz bu naxshini tunji qitim anglighanda choqum bashqa tilda anglighan BU esli nusqisi iken, kichik waqtimizdin qalghan eslimiler
TY - JOUR. T1 - Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. AU - Bains, Tarunpreet. AU - Chen, Andy I.. AU - Lemieux, Andrew. AU - Hayes-Lattin, Brandon M.. AU - Leis, Jose F.. AU - Dibb, William. AU - Maziarz, Richard T.. PY - 2014/3/1. Y1 - 2014/3/1. N2 - High-dose therapy with autologous stem cell transplant (autoSCT) is standard therapy for relapsed/refractory Hodgkin lymphoma, although the optimal conditioning regimen remains uncertain. We conducted a retrospective analysis of 100 consecutive patients with relapsed/refractory Hodgkin lymphoma who underwent autoSCT between 1998 and 2009. There were 60 patients who received busulfan, melphalan and thiotepa (BuMelTt) conditioning and 40 who received other common regimens. There were no significant differences in patient characteristics between the two groups. With a median follow-up of 4.3 years, the 5-year overall survival (OS) ...
Sigma-Aldrich offers abstracts and full-text articles by [Alberto Alvarez-Larrán, Luz Martínez-Avilés, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, María Luisa Antelo, Carmen Burgaleta, M Isabel Mata, Blanca Xicoy, Alejandra Martínez-Trillos, M Teresa Gómez-Casares, M Antonia Durán, Bárbara Marcote, Agueda Ancochea, Alicia Senín, Anna Angona, Montse Gómez, Vicente Vicente, Francisco Cervantes, Beatriz Bellosillo, Carles Besses].
This trial looked at treosulfan chemotherapy for children, young people and adults with Ewings sarcoma who already had treatment.
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation. 2016 ...
Learn about the causes, symptoms, diagnosis & treatment of Vascular Disorders of the Liver from the Professional Version of the Merck Manuals.
Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future
...WOBURN Mass. Oct. 18 2011 /- CBI is pleased to announc...Anchored by conference chairman Robert Besthof Vice President Comme...CMAC 2011 is the industrys only opportunity to participate in an exec... About CBI: ...,Full,Agenda,Announced,for,CMAC,2011,-,CBIS,2nd,Annual,Commercialization,and,Market,Access,Congress,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
Busulfan. Römpp CD 2006, Georg Thieme Verlag 2006 v t e. ...
Busulfan Risbridger, GP; Davies, A (June 1994). "Isolation of rat Leydig cells and precursor forms after administration of ...
2014). "Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem ... Carboplatin and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each person. Simple blood ... Chemotherapies with high risk include procarbazine and other alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ...
Research suggests it is less toxic than the alkyl sulfonate Busulfan. Jeswani G, Paul SD (2017). "Recent Advances in the ...
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. In 2017, CIRM awarded $2 million to a ... "Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1". New England Journal of Medicine. 380 (16): ...
Only cytotoxic drugs such as busulfan, hydroxyurea or interferon-alpha (rIFN-α) were utilized. Even though the first Bcr-Abl TK ...
Sem spadajo analogi dušikovega iperita (melfalan, klorambucil ...), alkilsulfonati (busulfan ...), epoksidi ... Zaviralci ...
"Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell ... Carboplatin[25]:4 and busulfan[26][27] dosing rely upon results from blood tests to calculate the optimal dose for each patient ... Most chemotherapy is delivered intravenously, although a number of agents can be administered orally (e.g., melphalan, busulfan ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ...
Busulfan is an example of a dialkylating agent: it is the methanesulfonate diester of 1,4-butanediol. Methanesulfonate can be ... mustard Melphalan Chlorambucil Ifosfamide Bendamustine Nitrosoureas Carmustine Lomustine Streptozocin Alkyl sulfonates Busulfan ...
Additionally, mice lacking PAX7 had delayed recovery of spermatogenesis following exposure to busulfan when compared to control ...
Chemotherapies with high risk include procarbazine and alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, ...
... is also used as an excipient in drugs, e.g. in Vumon (teniposide), Busulfex (busulfan) or Amsidine (amsacrine ...
Naruse, Takuji; Takahara, Masatoshi; Takagi, Michiaki; Oberg, Kerby C.; Ogino, Toshihiko (2007). "Busulfan-induced central ...
1996). "Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone ...
January 2012). "Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in ...
... busulfan, melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as ...
... busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma". Biol Blood Marrow ...
... cyclophosphamide and busulfan). Skin lesion James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin ...
took out and isolated SSCs from prepubertal and adult rhesus macaques before treating them with busulfan (an alkylating agent ...
... busulfan, capecitabine). University of Pittsburgh Medical Center National Cancer Institute in Bethesda, Maryland Albany Medical ...
... busulfan, capecitabine). Delcath Systems, Inc. (NASDAQ: DCTH) a specialty pharmaceutical and medical device company ...
Two main studies showed that treosulfan is at least as effective as busulfan, another medicine used to prepare patients for ... of patients given busulfan (with fludarabine). In an additional study in 70 children with blood cancers, 99% of children given ...
Infections Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, methotrexate, apomorphine, and ...
... busulfan, and chlorambucil) or radiation (therapeutic or accidental), or both (e.g., at the time of stem cell transplantation ... MDS after exposure to radiation or alkylating agents such as busulfan, nitrosourea, or procarbazine, typically occurs 3-7 years ...
Aviane Azathioprine Azithromycin Baclofen Balziva Bisoprolol Fumarate Bleomycin Budeprion Budesonide Buspirone Busulfan ...
... the person is treated with busulfan or melphalan to kill as many of the person's existing HSCs to increase the chances of the ...
... busulfan, cyclophosphamide, chlorambucil, and nitrosourea (e.g., carmustine). Also, some medicinal drugs used in cardiovascular ...
L01AA05 Chlormethine L01AA06 Ifosfamide L01AA07 Trofosfamide L01AA08 Prednimustine L01AA09 Bendamustine L01AB01 Busulfan ...
In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan ...
Concomitant use of acetaminophen within 72 hours of busulfan use can reduce busulfan clearance (resulting in increased busulfan ... Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). However, clinical studies of busulfan ... Oral bioavailability of busulfan shows a large interindividual variation. Taking busulfan on an empty stomach is recommended to ... Fludarabine + busulfan is a typical example of this use. Toxicity may include interstitial pulmonary fibrosis ("busulfan lung ...
Busulfan: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking busulfan,. *tell your doctor and pharmacist if you are allergic to busulfan, any other medications, or any of the ... Busulfan may increase the risk that you will develop other cancers. Talk to your doctor about the risks of taking busulfan. ... If you become pregnant while taking busulfan, call your doctor immediately. Busulfan may harm the fetus. ...
This page contains brief information about busulfan and a collection of links to more information about the use of this drug, ... MedlinePlus Information on Busulfan (Myleran) and Busulfan (Bulsulfex) - Lay language summaries of important information about ... Busulfan is approved to treat:. *Chronic myelogenous leukemia (CML). *It is used as palliative treatment. This use is approved ... More About Busulfan. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. ...
... busulfan) is a cancer medication used to treat chronic myelogenous leukemia (a type of blood cancer). Busulfex is not a cure ... Generic drug: busulfan. Brand name: Busulfex. What is Busulfex (busulfan), and how does it work?. Busulfex (busulfan) is a ... Itraconazole decreases busulfan clearance by up to 25%. Metronidazole decreases the clearance of busulfan to a greater extent ... Busulfex (bus ulfan) Injection causes severe and prolonged myelosuppression at the recommended dos age. Hematopoietic ...
306 medications are known to interact with busulfan. Includes Acidophilus (lactobacillus acidophilus), AmBisome (amphotericin b ... Show all medications in the database that may interact with busulfan.. Check for interactions with busulfan. Type in a drug ... A total of 306 drugs (1693 brand and generic names) are known to interact with busulfan. ... Common medications checked in combination with busulfan. *Acidophilus (lactobacillus acidophilus). *AmBisome (amphotericin b ...
BUSULFAN (UNII: G1LN9045DK) (BUSULFAN - UNII:G1LN9045DK) BUSULFAN. 6 mg in 1 mL. ... Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or ... 6.3 Oral Busulfan Literature Review 7 DRUG INTERACTIONS 7.1 Drugs that Decrease Busulfan Injection Clearance 7.2 Drugs that ... The molecular formula of busulfan is CH 3SO 2O(CH 2) 4OSO 2CH 3 and a molecular weight of 246 g/mole. Busulfan has the ...
... rather than busulfan-based regimen, German scientists have shown. ... Treosulfan Better Than Busulfan in Prep for HSCT. Liam ... Patients given treosulfan were more likely to have AML (70.5%) than MDS (29.5%), but the spread was more even in the busulfan ... The results showed that not only was a treosulfan-based regimen noninferior to one containing busulfan in terms of event-free ... HOUSTON - Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable ...
If you have an allergy to busulfan or any other part of this drug. ...
BUSULFAN (UNII: G1LN9045DK) (BUSULFAN - UNII:G1LN9045DK) BUSULFAN. 6 mg in 1 mL. ... Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or ... 6.3 Oral Busulfan Literature Review 7 DRUG INTERACTIONS 7.1 Drugs that Decrease Busulfan Injection Clearance 7.2 Drugs that ... Busulfan is dissolved in DMA, 3.3 mL and Polyethylene Glycol 400, NF 6.7 mL. The solubility of busulfan in water is 0.1 g per L ...
Concomitant use of acetaminophen within 72 hours of busulfan use can reduce busulfan clearance (resulting in increased busulfan ... Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). However, clinical studies of busulfan ... Oral bioavailability of busulfan shows a large interindividual variation.[6] Taking busulfan on an empty stomach is recommended ... Busulfan is metabolized via glutathione conjugation in the liver to inactive metabolites. Itraconazole can decrease busulfan ...
Make research projects and school reports about Busulfan easy with credible articles from our FREE, online encyclopedia and ... Busulfan Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Busulfan. Definition. Busulfan (also known by the ... Busulfan, when used for bone marrow transplants, is dosed by patient body weight. Busulfan is usually given at a dose of 4mg ... Busulfan is taken orally and comes in tablet form.. Recommended dosage. Busulfan can be taken following several different ...
Busulfan - An anticancer drug that belongs to the family of drugs called alkylating agents, is clearly explained in Medindia s ... Busulfan - Glossary. Written & Compiled by Medindia Content Team. Medically Reviewed by The Medindia Medical Review Team on May ... Medical Word - Busulfan. Ans : An anticancer drug that belongs to the family of drugs called alkylating agents. ...
... that is used as an antineoplastic drug in the treatment of chronic myelogenous leukemia.Origin of busulfan bu(tane) alteration ... busulfan. bu·sul·fan. noun. An alkylating agent, C6H14O6S2, that is used as an antineoplastic drug in the treatment of chronic ... Busulfan. (n.d.). In YourDictionary. Retrieved from https://www.yourdictionary.com/Busulfan ... Busulfan. (n.d.). In YourDictionary. Retrieved from https://www.yourdictionary.com/Busulfan ...
Busulfan) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related ... The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in ... Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%).. Metabolism: Busulfan is predominantly metabolized ... Oral Busulfan Literature Review: Four publications of randomized, controlled trials that evaluated a high-dose oral busulfan- ...
... includes busulfan (oral/injection) description, dosage and directions. ... Physician reviewed busulfan (oral/injection) (oral/injection) patient information - ... Busulfan (oral/injection). Generic Name: busulfan (oral/injection) (bue SUL fan). Brand Name: Busulfan, Busulfex, Myleran ... Take the busulfan oral tablet with a full glass of water.. Busulfan injection is given as an infusion into a vein in your upper ...
Busulfan belongs to the group of medicines known as alkylating agents. It seems to act by interfering with the function of the ... Since the growth of normal body cells may also be affected by busulfan, other effects will also occur. Some of these may be ... Before you begin treatment with busulfan, you and your doctor should talk about the benefits this medicine will do as well as ... Busulfan injection is used in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic ...
Information about this busulfan-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Thalassemia-Busulfan may cause increased pressure within the heart in children. Proper Use. A nurse or other trained health ... Busulfan must be given slowly, so the needle will remain in place for 2 hours. You may also receive medicines to help prevent ... Busulfan belongs to the group of medicines known as alkylating agents. It seems to act by interfering with the function of the ...
Busulfan is used to treat chronic myelogenous leukemia. Busulfan is usually administered as an oral tablet. 12 ... Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may ... Busulfan (Myleran®) is an alkylating agent that prevents DNA synthesis and transcription and induces (causes) nucleotide ... The most common adverse effect of busulfan is bone marrow depression which results in altered blood cell counts. For this ...
Busulfan Busulfan is used treat a certain type of chronic myelogenous leukemia (CML; a type of cancer of the white blood cells ... Busulfan Injection Busulfan injection is used to treat a certain type of chronic myelogenous leukemia (CML; a type of ... cells ... Cancers of the lung, breast, and ovary Examples: Busulfan (Myleran) Cyclophosphamide Temozolomide (Temodar) Caution: May damage ... Chemotherapy and hormonal medicines: Antiandrogens (Casodex, Flutamide, Nilutamide) Busulfan (Myleran) Cyclophosphamide ( ...
Drug: Busulfan Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation ... Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation. The safety and scientific validity of this study is the ... Drug Information available for: Busulfan Clofarabine Genetic and Rare Diseases Information Center resources: Myelodysplastic ... In this research study, the investigators are looking to see how well this new combination of busulfan and clofarabine works in ...
Busulfan Tablets)? Learn about drug imprint, side effects, uses (treating), dosage, interaction, overdose, and warnings. ... What is busulfan (Busulfan, Busulfex, Myleran)?. *What are the possible side effects of busulfan (Busulfan, Busulfex, Myleran)? ... What should I avoid while using busulfan (Busulfan, Busulfex, Myleran)?. *What other drugs will affect busulfan (Busulfan, ... What is busulfan (Busulfan, Busulfex, Myleran)?. Busulfan oral (taken by mouth) is used to treat the symptoms of chronic ...
djusting busulfan dosage based on gender has not been adequately studied. Race. djusting busulfan dosage based on race has not ... Busulfan is a presumed human carcinogen. Clinical Studies. Documentation of the safety and efficacy of busulfan as a component ... In the busulfan allogeneic stem cell transplantation clinical trial, all patients were treated with busulfan 0.8 mg/kg as a two ... Busulfan has not been studied in patients with renal impairment. Hepatic Impairment. Busulfan has not been administered to ...
... after the first dose of busulfan was measured in patients receiving a 16-dose course of busulfan as part of a BMT preparative ... Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.. Grochow LB1. ... High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. The dose-limiting ... In 27 patients who showed high AUCs (, 1,500 mumol.min/L) after the first dose, the fifth through 16th doses of busulfan were ...
ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic ... will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic ... Ammoscato will present on the handling and manufacture of the highly potent busulfan active pharmaceutical ingredient (API) as ... to Present Development of Highly Potent Anti-Cancer Drug Busulfan at AACR Annual Meeting ...
Busulfan injection. What is this medicine?. BUSULFAN (byoo SUL fan) is a chemotherapy drug. It is used prior to a stem cell ... an unusual or allergic reaction to busulfan, other chemotherapy agents, other medicines, foods, dyes, or preservatives ...
Busulfan (Science: chemical) An alkylating agent having a selective immunosuppressive effect on bone marrow. It has been used ... According to the fourth annual report on carcinogens (ntp 85-002, 1985), busulfan is listed as a known carcinogen. ... Busulfan. Revision as of 21:16, 3 October 2005 by WikiConvertor (Talk) ... Retrieved from "http://www.biology-online.org/bodict/index.php?title=Busulfan&oldid=18914" ...
Experimental: Busulfan + Fludarabine Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours ... Busulfan and Fludarabine in Patients With AML and MDS. The safety and scientific validity of this study is the responsibility ... Drug: Busulfan 130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting ... High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately ...
After busulfan treatment, the weight of the testes and the epididymal sperm count progressively decreased in the normal diet ... Male 4-week-old C57BL/6J mice were administered a single intraperitoneal injection of busulfan, and they were then fed a normal ... These results suggest that busulfan-induced aspermatogenesis is irreversible if appropriate treatment is not administered. ... to mice suffering from severe aspermatogenesis after busulfan treatment to determine whether TJ107 can recover spermatogenesis ...
Busulfan cancer chemotherapy drug molecule (alkylating agent). Atoms are represented as spheres with conventional colour coding ... Keywords: alkyl, alkylating, antineoplastic, artwork, atomic, busulfan, busulfane, cancer, cgi, chemical, chemistry, ... Caption: Busulfan cancer chemotherapy drug molecule (alkylating agent). Atoms are represented as spheres with conventional ...
On this page about Busulfan (Apotex) you will find information relating to side effects, age restrictions, food interactions, ... Other medicines containing the same active ingredients: busulfan *Can I take Busulfan (Apotex) in sport? Find out on the ASADA ... For the active ingredient busulfan. You should seek advice from your doctor or pharmacist about taking this medicine. They can ... Busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to ...
  • Myleran is supplied in white film coated tablets with 2 mg of busulfan per tablet. (wikipedia.org)
  • This use is approved for the Myleran brand of busulfan. (cancer.gov)
  • MedlinePlus Information on Busulfan (Myleran) and Busulfan (Bulsulfex) - Lay language summaries of important information about these drugs. (cancer.gov)
  • Busulfan (also known by the brand name Myleran) is a chemotherapy medicine used to treat cancer by destroying cancerous cells. (encyclopedia.com)
  • What are the possible side effects of busulfan (Busulfan, Busulfex, Myleran)? (rxlist.com)
  • What is the most important information I should know about busulfan (Busulfan, Busulfex, Myleran)? (rxlist.com)
  • What should I discuss with my healthcare provider before using busulfan (Busulfan, Busulfex, Myleran)? (rxlist.com)
  • Myleran (Busulfan) is a chemotherapy medication used in the treatment of some types of leukemia . (healthtap.com)
  • When taken as directed, the active ingredient in Myleran, called Busulfan, will work to interfere with the DNA so the cancer cells cannot 'read' their codes in order to be able to copy the DNA and create even more cancer cells. (discountdrugsfromcanada.com)
  • Busulfan tablets (Myleran) for leukaemia. (high-kick.ru)
  • Busulfex is supplied as an intravenous solution with 6 mg/ml busulfan. (wikipedia.org)
  • Busulfex has proved equally effective as oral busulfan, with presumedly less toxic side effects. (wikipedia.org)
  • This use is approved for the Busulfex brand of busulfan. (cancer.gov)
  • What is Busulfex (busulfan), and how does it work? (medicinenet.com)
  • Busulfex ( busulfan ) is a cancer ( antineoplastic ) medication used to treat the symptoms of chronic myelogenous leukemia (a type of blood cancer ). (medicinenet.com)
  • Discontinue iron chelating agents well in advance of administration of Busulfex to avoid increased exposure to busulfan. (medicinenet.com)
  • Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to (less than 72 hours) or concurrent with Busulfex may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues. (medicinenet.com)
  • BUSULFEX ® (busulfan) Injection is intended for intravenous administration. (rxlist.com)
  • Each vial of BUSULFEX contains 60 mg (6 mg/mL) of busulfan, the active ingredient, a white crystalline powder with a molecular formula of CH 3 SO 2 O(CH 2 ) 4 OSO 2 CH 3 and a molecular weight of 246 g/mole. (rxlist.com)
  • The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP as recommended for infusion reflects the pH of the diluent used and ranges from 3.4 to 3.9. (rxlist.com)
  • The diluent quantity should be 10 times the volume of BUSULFEX, so that the final concentration of busulfan is approximately 0.5 mg per mL. (rxlist.com)
  • Captisol Enabled™ Busulfan is designed to remove the toxic excipients N,N-dimethylacetamide (DMA) and polyethylene glycol (PEG), which are present in the marketed product IV BUSULFEX® (busulfan). (ligand.com)
  • rATG on days -3, -2 and -1 Other Names: Fludara Busulfex Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI) Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant. (aamds.org)
  • After 2002, a great interest has appeared for intravenous presentations of busulfan. (wikipedia.org)
  • As an adjunct therapy with cyclophosphamide for conditioning prior to bone marrow transplantation in adults and children >12 kg, intravenous (IV) busulfan (Bulsulfex) is dosed at 0.8 mg/kg every six hours for 16 doses (four days). (wikipedia.org)
  • 12 kg, intravenous (IV) busulfan (Bulsulfex) is dosed at 0.8 mg/kg every six hours for 16 doses (four days). (wikipedia.org)
  • To administer multiple doses of an intravenous formulation of busulfan (Bu) at a dose adjusted to yield a blood drug level with a median daily area under the plasma concentration curve (AUC) of approximately 6,500 µMol-min. (clinicaltrials.gov)
  • Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour. (clinicaltrials.gov)
  • Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial," Cancer , vol. 121, no. 4, pp. 562-569, 2015. (hindawi.com)
  • Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination," Biology of Blood and Marrow Transplantation , vol. 17, no. 1, pp. 117-123, 2011. (hindawi.com)
  • Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma. (centerwatch.com)
  • Personalizing intravenous busulfan doses to a target plasma concentration at steady state ( C ss ) is an essential component of hematopoietic cell transplantation (HCT). (aacrjournals.org)
  • The study included 239 participants - both children and adults - who underwent allo-HCT with intravenous busulfan between July 2011 and July 2016 at the University Medical Center in Utrecht, Netherlands. (oncologynurseadvisor.com)
  • While intravenous (IV) formulations of busulfan are now available and have lower incidences of toxicity and treatment related mortality compared to oral dosing, it still displays large pharmacokinetic variability. (springer.com)
  • Busulfan Injection is packaged as a sterile solution in 10 mL single-dose clear glass vials each containing 60 mg of busulfan at a concentration of 6 mg per mL for intravenous use, NDC 16729-351-03. (myhealthbox.eu)
  • Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. (duke.edu)
  • Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. (cdc.gov)
  • Kinetics-based dose targeting is often conducted in hematopoietic cell transplant (HCT) patients conditioned with intravenous (IV) or oral busulfan to lower rates of rejection, nonrelapse mortality, and relapse. (cdc.gov)
  • Both IV and oral formulations require prophylactic antiemetic agents administered prior to the busulfan dose and scheduled antiemetics administered thereafter. (wikipedia.org)
  • Busulfan therapeutic drug monitoring is completed based on trough (pre-dose) levels with a target six-hour area under the curve (AUC) of between 900 and 1500 micromolxmin. (wikipedia.org)
  • However, clinical studies of busulfan were completed with patients taking phenytoin, so no empiric dose adjustment is necessary if patients are taking phenytoin with busulfan. (wikipedia.org)
  • Your doctor may need to change your dose or tell you to stop taking busulfan for a period of time to allow your blood count to return to normal if it has dropped too low. (medlineplus.gov)
  • Your doctor may adjust your dose of busulfan depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
  • Busulfan is a 2mg oral tablet, and patients may need to take more than one tablet at a time depending on the dose. (encyclopedia.com)
  • The dose of busulfan for use in combination with other chemotherapy drugs before a bone marrow transplant is much larger than leukemia dosing. (encyclopedia.com)
  • In bone marrow transplant patients, the dose of busulfan that is given in combination with other chemotherapy drugs is intended to cause complete bone marrow destruction prior to bone marrow transplant. (encyclopedia.com)
  • High-dose busulfan may affect fertility (ability to have children) in women, either temporarily or permanently. (drugs.com)
  • Since busulfan injection is given by a healthcare professional, you are not likely to miss a dose. (drugs.com)
  • The most frequent serious consequence of treatment with busulfan at the recommended dose and schedule is profound myelosuppression , occurring in all patients. (wikidoc.org)
  • Seizures have been reported in patients receiving high-dose oral busulfan at doses producing plasma drug levels similar to those achieved following the recommended dosage of busulfan. (wikidoc.org)
  • High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. (nih.gov)
  • The dose-limiting toxicity of busulfan in BMT regimens is hepatic veno-occlusive disease (VOD), which occurs in approximately 20% to 40% of patients. (nih.gov)
  • The area under the curve of time versus concentration (AUC) after the first dose of busulfan was measured in patients receiving a 16-dose course of busulfan as part of a BMT preparative regimen. (nih.gov)
  • 1,500 mumol.min/L) after the first dose, the fifth through 16th doses of busulfan were decreased. (nih.gov)
  • this information will be used to determine the subsequent high-dose busulfan doses. (clinicaltrials.gov)
  • Patients who do not agree to the optional pharmacology procedure will receive a fixed dose of busulfan as has previously been done for 3 years. (clinicaltrials.gov)
  • High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately after fludarabine. (clinicaltrials.gov)
  • Between Days -15 and -8, you will receive a low-level "test" dose of busulfan by vein over about 45 minutes to 1 hour. (knowcancer.com)
  • Test doses are used to study how your body breaks down busulfan and decide the dose of busulfan that you will receive. (knowcancer.com)
  • Blood (about 1 teaspoon each time) will then be drawn for PK testing up to 11 times over the 11 hours after the busulfan test dose. (knowcancer.com)
  • If for any reason it is not possible for the PK tests to be performed, you will receive the standard dose of busulfan. (knowcancer.com)
  • On Days -6 through -3, you will receive clofarabine by vein over 1 hour, followed by your dose of busulfan by vein over 3 hours. (knowcancer.com)
  • If for any reason you could not have the PK tests performed, you will receive the standard busulfan dose on these days. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating doses of busulfan until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
  • HRD recipients received low-dose cyclophosphamide for 2 days, fludarabine for 5 days, 2 to 3 days of busulfan depending on cytogenetics, and 200 cGy total body irradiation. (unboundmedicine.com)
  • Busulfan, at a dose of 2 mg/day, is an effective option for elderly patients with PV or ET who fail to hydroxyurea, but a significant rate of transformation was observed. (sigmaaldrich.com)
  • The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. (clinicaltrials.gov)
  • Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. (clinicaltrials.gov)
  • To assess safety and toxicity of the addition of busulfan added to an established fludarabine and low-dose total-body irradiation (TBI) conditioning regimen for non-myeloablative allogeneic transplantation in patients with hematologic malignancies. (clinicaltrials.gov)
  • Since the polymorphic mu-class GST catalyzed busulfan conjugation, we examined busulfan clearance in 50 patients undergoing high-dose busulfan before bone marrow transplantation. (aspetjournals.org)
  • This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation. (aamds.org)
  • Subjects will be randomly assigned to receive one of 2 conditioning regimen: fludarabine and busulfan, or fludarabine busulfan and low dose total body irradiation (TBI). (aamds.org)
  • Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose) Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant. (aamds.org)
  • It is the consensus of the eviQ BMT Reference Committee not to divide the dose of busulfan as per Rambaldi 2015. (eviq.org.au)
  • Objective: To examine the effi cacy and safety of hematopoietic stem cell transplantation (HSCT) after low-dose (50-65 %) Busulfan, full-dose Fludarabine conditioning and in-vivo T-cell depletion in high-risk pediatric and adult chronic granulomatous disease (CGD) patients. (aspergillus.org.uk)
  • Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of hematopoietic stem cell transplantation (HSCT). (uu.nl)
  • For the 12 months ending 30 September 2017, the US sales for Busulfan Injection, 60 mg/10 ml (6 mg/ml) single-dose vial were approximately USD97m, according to IQVIA. (thefreedictionary.com)
  • Oral lorazepam prevents seizure during high-dose busulfan in c. (mysciencework.com)
  • Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. (mysciencework.com)
  • High-dose Busulfan in combination chemotherapy has been used commonly for hematopoietic stem cell transplantation. (mysciencework.com)
  • None of the patients developed seizure while receiving oral lorazepam or within 72 hours of the last dose of Busulfan. (mysciencework.com)
  • In the authors' experience, oral lorazepam is a useful anticonvulsant prophylaxis for children receiving high-dose busulfan. (mysciencework.com)
  • High-dose busulfan used in conditioning regimens for haematopoietic stem cell transplantation may increase the risk of lateonset haemorrhagic cystitis. (pocketdrugguide.com)
  • Dose-dependent veno-occlusive disease (VOD) has been reported in 20 to 40% of patients receiving high-dose busulfan before bone marrow transplantation. (pocketdrugguide.com)
  • A reduced incidence of hepatic VOD has been seen in those patients given high-dose busulfan and cyclophosphamide when the first dose of cyclophosphamide has been delayed for more than 24 hours after the last dose of busulfan. (pocketdrugguide.com)
  • High-dose busulfan, used in conditioning regimens for bone marrow transplantation, has been associated with the development of convulsions, both generalised and myoclonic. (pocketdrugguide.com)
  • a,b) Messenger RNA from the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) was assayed by quantitative RT-PCR and normalized to control, showing that all were upregulated after busulfan treatment in U2OS (a) and MG-63 cells (b). (c) Dose-dependent and time-dependent effect of busulfan on the activation of miR-429. (nih.gov)
  • Finally, fter determining the effective dose of busulfan, Vitamin E was injected to the mice as an antioxidant enzyme and its effects on semen parameters and testis tissue was examined after one month. (ac.ir)
  • After finding the most damaging dose of busulfan (40 mg/kg ) in destruction of testis tissue, these mice were injected by vitamine E. The results showed that the oxidative stress and percentage of abnormal sperm were decreased in Busulfan-treated mice that exposed a dose of 100 mg/kg vitamin E. The number of sperm and antioxidant activity of catalase was increased. (ac.ir)
  • Optimal dose of busulfan for depleting testicular germ cells of recipient mice before spermatogonial transplantation. (ac.ir)
  • Busulfan a member of the group of chemotherapy drugs known as alkylating agents. (encyclopedia.com)
  • Patients who are pregnant or are trying to become pregnant should notify their physician before taking busulfan (or any chemotherapy medication). (encyclopedia.com)
  • BUSULFAN (byoo SUL fan) is a chemotherapy drug. (ahealthyme.com)
  • Busulfan cancer chemotherapy drug molecule (alkylating agent). (sciencephoto.com)
  • RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. (clinicaltrials.gov)
  • It is estimated that this type of complication after allo-HSCT was observed in 0-70% of cases, and the risk of these adverse events increases in the group of patients with liver damage, in which myeloablative chemotherapy or busulfan therapy was used [25]. (thefreedictionary.com)
  • Busulipo has been developed by Pharmalink as a liposome/lipid complex formulation that improves the safety and stability of the chemotherapy agent busulfan , and is aimed at becoming the new gold standard for use in conditioning prior to HSCT. (thefreedictionary.com)
  • Busulfan is a chemotherapy medicine for treatment of cancer. (ac.ir)
  • These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. (nih.gov)
  • See full prescribing information for BUSULFAN INJECTION. (nih.gov)
  • Seizures: Initiate anticonvulsant prophylactic therapy prior to treatment with Busulfan Injection. (nih.gov)
  • Drugs that Increase Busulfan Injection Clearance: Phenytoin. (nih.gov)
  • Busulfan Injection causes severe and prolonged myelosuppression at the recommended dosage. (nih.gov)
  • Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. (nih.gov)
  • Administer Busulfan Injection in combination with cyclophosphamide as a conditioning regimen prior to bone marrow or peripheral blood progenitor cell replacement. (nih.gov)
  • Busulfan injection is used together with a medicine called cyclophosphamide , to prepare your body to receive a stem cell transplant from a donor's bone marrow. (drugs.com)
  • Busulfan injection is given as an infusion into a vein in your upper chest (central IV). (drugs.com)
  • Appropriate studies have not been performed on the relationship of age to the effects of busulfan injection in the pediatric population. (mayoclinic.org)
  • Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of busulfan injection in the elderly. (mayoclinic.org)
  • Busulfan (injection) is an alkylating agent that is FDA approved for the treatment of chronic myelogenous leukemia . (wikidoc.org)
  • Male 4-week-old C57BL/6J mice were administered a single intraperitoneal injection of busulfan, and they were then fed a normal diet for 60 days and then a TJ107 diet or TJ107-free normal diet for another 60 days. (mdpi.com)
  • Busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation. (healthdirect.gov.au)
  • Risk Summary Busulfan Injection can cause fetal harm when administered to a pregnant woman based on animal data. (myhealthbox.eu)
  • Busulfan Injection is distributed as a unit carton of eight vials NDC 16729-351-92. (myhealthbox.eu)
  • Unopened vials of Busulfan Injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time. (myhealthbox.eu)
  • Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. (myhealthbox.eu)
  • Busulfan Injection is a cytotoxic drug. (myhealthbox.eu)
  • Why is busulfan injection medication prescribed? (ndclist.com)
  • Physician reviewed busulfan (oral/injection) (oral/injection) patient information - includes busulfan (oral/injection) description, dosage and directions. (usarx.com)
  • What Is Busulfan Injection Used For? (emedtv.com)
  • Interested in a Discount on Busulfan Injection? (emedtv.com)
  • How Busulfan Injection works, side effects, interactions and precautions. (navigatingcare.com)
  • Busulfan injection may cause seizures during therapy with the medication. (navigatingcare.com)
  • Your doctor will give you another medication to help prevent seizures before and during therapy with busulfan injection. (navigatingcare.com)
  • Busulfan is used in pediatrics and adults in combination with cyclophosphamide or fludarabine/clofarabine as a conditioning agent prior to bone marrow transplantation, especially in chronic myelogenous leukemia (CML) and other leukemias, lymphomas, and myeloproliferative disorders. (wikipedia.org)
  • Cardiac tamponade has been reported in pediatric patients with thalassemia who received high doses of oral busulfan and cyclophosphamide. (nih.gov)
  • Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide. (thefreedictionary.com)
  • 3) These include the antiarrhythmic drug amiodarone, the chemotherapeutic agents bleomycin, busulfan , carmustine and cyclophosphamide, the immunosuppressive drugs sirolimus and everolimus and many others. (thefreedictionary.com)
  • Others (cyclophosphamide, busulfan , and carmustine) can cause it even years after completion of therapy. (thefreedictionary.com)
  • busulfan , melphalan, cyclophosphamide) doxorubicin, daunorubicin cause stomatitis and patients with hematological malignancies are more prone to the occurrence of oral complications [7]. (thefreedictionary.com)
  • The goal of this clinical research study is to learn if busulfan with cyclophosphamide (when given with other helper drugs listed below) can help control the diseases listed above when given before a stem cell transplant. (sparkcures.com)
  • You will also receive other medicines to help prevent certain side effects of busulfan. (drugs.com)
  • PURPOSE: This phase I/II trial is studying the side effects of giving busulfan and fludarabine together with total-body irradiation and to see how well they work in treating patients who are undergoing a donor stem cell transplant for hematologic cancer. (clinicaltrials.gov)
  • 60 years with AML in first complete remission (CR1), that had received an alloSCT following NMA conditioning, i.e. either fludarabine/busulfan (FB2) or fludarabine/total-body-irradiation-2Gy (FluTBI2Gy). (rug.nl)
  • Toxicity may include interstitial pulmonary fibrosis ("busulfan lung"), hyperpigmentation, seizures, hepatic (veno-occlusive disease) (VOD) or sinusoidal obstruction syndrome (SOS), emesis, and wasting syndrome. (wikipedia.org)
  • metronidazole coadministration has been associated with increased busulfan toxicity. (medicinenet.com)
  • Busulfan was stopped in 27 patients (75 %) due to CHR achievement in 18 cases (67 %), hematological toxicity in 8 cases (30 %), and disease transformation in 1 case. (sigmaaldrich.com)
  • Busulfan is known to cause several adverse effects including reproductive toxicity in humans. (iranjournals.ir)
  • Garlic (Allium sativum) , a widely distributed medicinal plant, is highly regarded for its medicinal activities including antioxidant property.This study was conducted to assess whether garlic extract could serve as protective agents against testicular toxicity during busulfan treatment in a mice model.Seventy-two adult male mice were randomly divided into nine groups. (iranjournals.ir)
  • Busulfan toxicity involving the liver was also reported in a patient who had taken busulfan for 54 months, while hepatitis possibly associated with busulfan therapy has also been described. (pocketdrugguide.com)
  • another (GSK) lists concurrent use of multiple alkylating agents, or total doses of busulfan in excess of 16 mg/kg, as possible risk factors. (pocketdrugguide.com)
  • HOUSTON - Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) about to undergo allogeneic hematopoietic cell transplantation (HSCT), say German researchers reporting results from a phase 3 study. (medscape.com)
  • The results showed that not only was a treosulfan-based regimen noninferior to one containing busulfan in terms of event-free survival, but that it was associated with significantly improved overall survival and complete donor-type chimerism. (medscape.com)
  • The patients were randomly assigned in a 1:1 fashion to a treosulfan- or busulfan-based reduced intensity conditioning regimen, with the primary objective being to show at least the noninferiority of the treosulfan-based regimen in terms of event-free survival. (medscape.com)
  • The final analysis set consisted of 283 patients who received the busulfan-based regimen and 268 who were treated with treosulfan prior to HSCT. (medscape.com)
  • Beelen reported that the rates of early adverse events were comparable between the treosulfan and busulfan groups, whether looking at all grades, grades III-IV, or regimen-related grade III-IV events. (medscape.com)
  • Patients given a treosulfan-based regimen prior to HSCT were significantly more likely to achieve complete hematopoietic chimerism after transplantation than those treated with a busulfan-based regimen, at 93.2% vs 83% (adjusted P = .0159). (medscape.com)
  • The conditioning regimen consists of the following drugs: Busulfan and Clofarabine. (clinicaltrials.gov)
  • To describe the plasma pharmacokinetics of busulfan when administered intravenously in this regimen. (clinicaltrials.gov)
  • Here, we describe the results of a prospective study of HSCT in 22 patients with GATA2 deficiency using a busulfan-based conditioning regimen. (unboundmedicine.com)
  • Nonmyeloablative-conditioning regimen: Patients receive busulfan IV on day -5 and fludarabine IV over 30 minutes on days -4 to -2. (clinicaltrials.gov)
  • I. To compare progression free survival of two schedules of venetoclax, timed sequential busulfan, cladribine and fludarabine conditioning regimen in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). (centerwatch.com)
  • In this study we will be comparing in a randomized fashion the standard regimen to a regimen of fludarabine, busulfan and TBI. (aamds.org)
  • This is a prospective study using oral lorazepam together with busulfan-based conditioning regimen in 30 children undergoing hematopoietic stem cell transplantation. (mysciencework.com)
  • Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. (duke.edu)
  • We have conducted a phase II trial exploring the combination of busulfan (16 mg/kg) and etoposide (60 mg/kg) in an attempt to improve antitumor efficacy using this novel preparative regimen. (duke.edu)
  • The use of nucleoside analogs such as fludarabine (Flu) in combination with i.v. busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). (duke.edu)
  • This is a multicenter retrospective comparison of 2 myeloablative conditioning regimens in 454 patients with acute myeloid leukemia (AML) in remission: busulfan (4 days) and fludarabine (BUFLU) versus thiotepa, busulfan, and fludarabine (TBF). (elsevier.com)
  • Find Clinical Trials for Busulfan - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
  • The researchers compared the effect of treosulfan/ fludarabine regimens with those containing busulfan/fludarabine prior to HSCT in more 550 patients with AML or MDS who were either aged 50 to 70 years or who had comorbidities. (medscape.com)
  • Patients given treosulfan were more likely to have AML (70.5%) than MDS (29.5%), but the spread was more even in the busulfan group, at 57.5% with AML and 42.5% with MDS. (medscape.com)
  • A similar pattern was seen for serious adverse events, although treosulfan patients had more life-threatening serious adverse events than those given busulfan, at 4.8% and 2.8%, respectively, and had more fatal events, at 3% vs 2.1%, respectively. (medscape.com)
  • If nausea and vomiting are a problem, patients can be given medications known as antiemetics before receiving busulfan to help prevent or decrease these side effects. (encyclopedia.com)
  • Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may have harmful affects on the developing fetus. (cancerquest.org)
  • Busulfan can cause interstitial pneumonitis, as such patients should be monitored for pulmonary issues. (cancerquest.org)
  • There is limited information regarding Off-Label Guideline-Supported Use of Busulfan in adult patients. (wikidoc.org)
  • The effectiveness of busulfan in the treatment of CML has not been specifically studied in pediatric patients. (wikidoc.org)
  • Absolute neutrophil counts dropped below 0.5×109/L at a median of 4 days post-transplant in 100% of patients treated in the busulfan clinical trial. (wikidoc.org)
  • Patients receive intrathecal busulfan twice a week, at least 3 days apart, for 2 weeks. (knowcancer.com)
  • Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. (sigmaaldrich.com)
  • The efficacy of busulfan in patients with advanced PV or ET refractory or intolerant to hydroxyurea was assessed in 36 patients (PV n = 15, ET n = 21) treated for a median of 256 days. (sigmaaldrich.com)
  • Time to CHR was shorter in patients treated with ≥14 mg of busulfan per week than with lower doses (141 versus 336 days, p = 0.01). (sigmaaldrich.com)
  • To assess the non-relapse mortality 1-year after conditioning with busulfan and fludarabine/TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease. (clinicaltrials.gov)
  • ARM I: Patients receive venetoclax orally (PO) once daily (QD) on days -22 to -3 and busulfan intravenously (IV) over 3 hours on days -13 and -12. (centerwatch.com)
  • Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3. (centerwatch.com)
  • From July 1983 to January 1991, 441 CML patients were randomized to receive hydroxyurea or busulfan. (uni-bonn.de)
  • The median survival of the busulfan treated Philadelphia-positive patients is 45.4 months and of the hydroxyurea group 58.2 months (P = .008). (uni-bonn.de)
  • The 23 patients with primary hydroxyurea had a median survival of 5.6 years, the 41 patients with primary busulfan therapy a median survival of 2.7 years (P = .02). (uni-bonn.de)
  • The combination of fludarabine and busulfan is the current standard of care for patients with myeloid malignancies (AML, CML and other myeloproliferative disorders, or MDS) undergoing allogeneic transplantation at HUMC. (aamds.org)
  • Researchers compared models for determining cumulative exposure of busulfan in adult and pediatric patients receiving the drug prior to allo-HCT. (oncologynurseadvisor.com)
  • Therapeutic drug monitoring may prevent severe under and/or over exposure of busulfan in patients undergoing allo-HCT, according to study results presented at ESMO Congress 2019 in Barcelona, Spain. (oncologynurseadvisor.com)
  • Patients received busulfan daily for 4 consecutive days, and busulfan levels were measured on days 1 and 4. (oncologynurseadvisor.com)
  • Pediatric patients received a therapeutic drug monitoring aiming at a cumulative AUC of Busulfan between 45 to 65 mg/L x h. (aspergillus.org.uk)
  • Two patients with a low cumulative AUC for Busulfan under 45 mg/L x h had autologuous reconstitution. (aspergillus.org.uk)
  • Busulfan is less effective in patients without the Philadelphia chromosome. (rxwiki.com)
  • Busulfan is a prescription medication used in combination with other medications to destroy bone marrow and cancer cells in preparation for a bone marrow transplant in patients with chronic myelogenous leukemia , or CML. (rxwiki.com)
  • The average (± standard deviation) busulfan clearance was 3.2 ± 0.56 mL/min/kg in the separate population of 95 patients who received oral busulfan and 103 ± 24 ml/min/m(2) in the 57 patients who received IV busulfan. (cdc.gov)
  • Post-hoc IV busulfan clearance estimates in patients with GSTA1*A/*A, GSTA1*A/*B and GSTA1*B/*B genotypes. (umn.edu)
  • In this research study, the investigators are looking to see how well this new combination of busulfan and clofarabine works in reduced intensity allogeneic stem cell transplantation. (clinicaltrials.gov)
  • Busulfan should be administered under the supervision of a qualified physician experienced in hematopoietic stem cell transplantation . (wikidoc.org)
  • The following warnings pertain to different physiologic effects of busulfan in the setting of allogeneic transplantation . (wikidoc.org)
  • Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. (nih.gov)
  • Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation," International Journal of Hematology , vol. 93, no. 4, pp. 509-516, 2011. (hindawi.com)
  • Ligand is developing a novel Captisol®-based formulation of Busulfan for use as a conditioning agent prior to hematopoietic stem cell transplantation. (ligand.com)
  • Prior to allogenic hematopoietic cell transplantation (allo-HCT), the drug busulfan needs to accumulate to a given therapeutic range of 80-100 mg*hr/L. However, there is known to be within-person variability in how quickly busulfan is cleared from the body. (oncologynurseadvisor.com)
  • Boss J, Langenhorst J, Lalmohamed A, Van Der Linden P, Boelens JJ, Van Maarseveen E. The influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation. (oncologynurseadvisor.com)
  • Slattery JT, Risler LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. (springer.com)
  • busulfan monitoring in bone marrow transplantation), a few calibration measurements that could be collected at random instead of the current strict timing required for current TDM would be a welcome change. (thefreedictionary.com)
  • Busulfan treatment is followed by bone marrow transplantation (BMT), with T-cell depleted donor bone marrow bearing a different congenic marker (CD45.2) to that of the host mouse (CD45.1). (bio-protocol.org)
  • Busulfan is also used during preparation for stem cell transplantation . (high-kick.ru)
  • Supplementation of TJ107 can completely recover the injured seminiferous epithelium via normalization of the macrophage migration and reduction of the expressions of Tool-like receptor (TLR) 2 and TLR4, suggesting that TJ107 has a therapeutic effect on busulfan-induced aspermatogenesis. (mdpi.com)
  • Parenteral administration of Busulfan (BU) conquers the bioavailability and biovariability related issues of oral BU by maintaining the plasma drug concentration in therapeutic range with minimal fluctuations thereby significantly reducing the side effects. (ovid.com)
  • We strongly advocate for the use of a [pharmacokinetic] model aided therapeutic drug monitoring anticipating a decrease in busulfan clearance," write the researchers. (oncologynurseadvisor.com)
  • Furthermore, Hachimijiogan and/or Hochuekkito were already determined in busulfan-treatment induced aspermatogenesis in mice and showed the different therapeutic effect on reproductive toxicities. (nii.ac.jp)
  • At the American Association for Cancer Research annual meeting this month, Vince Ammoscato, Vice President of Operations at Ash Stevens, Inc. will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). (prweb.com)
  • Vince Ammoscato, Vice President of Operations at Ash Stevens Inc. (ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). (prweb.com)
  • However, some do not consider the routine use of prophylactic antiepileptics justified, and the potential for phenytointo increase the metabolism of busulfan, thereby possibly decreasing its myeloablative efficacy, has been pointed out. (pocketdrugguide.com)
  • Do not stop taking busulfan without talking to your doctor. (medlineplus.gov)
  • Do not stop taking busulfan without speaking with your doctor first. (high-kick.ru)
  • Tsumura Co., Ltd., Tokyo, Japan) to mice suffering from severe aspermatogenesis after busulfan treatment to determine whether TJ107 can recover spermatogenesis. (mdpi.com)
  • Goshajinkigan completely recover the severe aspermatogenesis after busulfan treatment in mice. (ac.ir)
  • Busulfan tablets are also used in combination with other drugs to destroy the bone marrow and cancer cells in preparation for a bone marrow transplant. (medlineplus.gov)
  • A total of 306 drugs (1693 brand and generic names) are known to interact with busulfan . (drugs.com)
  • Interestingly, the use of other drugs, such as paracetamol and anticonvulsants, predicted the decline in busulfan clearance over time. (oncologynurseadvisor.com)
  • Busulfan belongs to a group of drugs called alkylating agents. (rxwiki.com)
  • If you take busulfan with other medications that may cause a low blood count, the side effects of the medications may be more severe. (medlineplus.gov)
  • Take busulfan at around the same time every day. (medlineplus.gov)
  • Take busulfan exactly as directed. (medlineplus.gov)
  • Can I take Busulfan (Apotex) in sport? (healthdirect.gov.au)
  • Take Busulfan exactly as directed by your doctor or according to the instructions on the label. (mims.com)
  • You can take busulfan tablets before or after meals. (high-kick.ru)
  • You may need to take busulfan for several weeks or months. (high-kick.ru)
  • Seizures and VOD are serious concerns with busulfan therapy and prophylaxis is often utilized to avoid these effects. (wikipedia.org)
  • Levetiracetam, has shown efficacy for the prophylaxis against busulfan-induced seizures. (wikipedia.org)
  • Benzodiazepines can also be used for busulfan-induced seizures. (wikipedia.org)
  • You may also receive medicines to help prevent seizures after using busulfan. (mayoclinic.org)
  • Clobazam has been suggested as an alternative to phenytoin for prophylaxis of busulfan-induced seizures. (pocketdrugguide.com)
  • Busulfan can cause a severe decrease in the number of blood cells in your bone marrow. (medlineplus.gov)
  • Busulfan, when used for bone marrow transplants, is dosed by patient body weight. (encyclopedia.com)
  • Nausea, vomiting, loss of appetite, mouth sores, and diarrhea are rare side effects from busulfan at normal doses, but are common at the higher doses used for bone marrow transplant. (encyclopedia.com)
  • The most common adverse effect of busulfan is bone marrow depression which results in altered blood cell counts. (cancerquest.org)
  • Busulfan is an anti-cancer chemotherapeutic drug and is often used as conditioning regimens prior to bone marrow transplant for treatment of chronic myelogenous leukemia. (mdpi.com)
  • Busulfan is a commonly used antineoplastic agent to condition/ablate bone marrow cells before hematopoietic stem cell transplant. (springer.com)
  • The major adverse effect of busulfan with standard doses is bone-marrow depression, manifest as leucopenia, thrombocytopenia, and sometimes, anaemia. (pocketdrugguide.com)
  • The nadir of the granulocyte count usually occurs after about 10 to 30 days with recovery occurring over up to 5 months, but busulfan has sometimes caused irreversible or extremely-prolonged bone-marrow depression. (pocketdrugguide.com)
  • We performed a dual-center, phase 1-2 safety and efficacy study of a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells after low-exposure, targeted busulfan conditioning in eight infants with newly diagnosed SCID-X1. (cdc.gov)
  • Bone marrow harvest, busulfan conditioning, and cell infusion had no unexpected side effects. (cdc.gov)
  • Also tell your doctor if you have taken busulfan before, but your cancer did not respond to the medication. (medlineplus.gov)
  • Busulfan may also be used for purposes not listed in this medication guide. (drugs.com)
  • Busulfan comes as a tablet to take by mouth once a day. (medlineplus.gov)
  • Busulfan is taken orally and comes in tablet form. (encyclopedia.com)
  • Take the busulfan oral tablet with a full glass of water. (drugs.com)
  • Busulfan is usually administered as an oral tablet. (cancerquest.org)
  • Rarely, progressive interstitial pulmonary fibrosis, known as 'busulfan lung', can occur on prolonged treatment. (pocketdrugguide.com)
  • THT+ formation rate increased linearly with busulfan concentration up to its solubility limit for all GST isoforms. (aspetjournals.org)
  • Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). (wikipedia.org)
  • Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase. (medicinenet.com)
  • Busulfan was approved by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML) in 1999. (wikipedia.org)
  • Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug's relative low cost. (wikipedia.org)
  • We also used gas chromatography-electron capture detection and pharmacokinetic models to assess whether excessive exposure to busulfan correlates with an increased risk of VOD. (nih.gov)
  • Decreased clearance of busulfan was observed with concomitant use with deferasirox. (medicinenet.com)
  • Haemorrhagic cystitis occurred in a patient who had received prolonged therapy with busulfan. (pocketdrugguide.com)
  • Many other medications may also interact with busulfan, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)
  • Show all medications in the database that may interact with busulfan. (drugs.com)
  • Your doctor will order laboratory tests before, during and after your treatment to check your body's response to busulfan to see if your blood cells are affected by this drug. (medlineplus.gov)
  • This page contains brief information about busulfan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. (cancer.gov)
  • If you have an allergy to busulfan or any other part of this drug. (mskcc.org)
  • Busulfan is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. (wikidoc.org)
  • Busulfan is effective as first-line therapy, but there is scarce information on this drug as second-line treatment. (sigmaaldrich.com)
  • Captisol Enabled™ Busulfan has the potential to improve tolerance, which may result in higher drug exposure and longer duration of therapy. (ligand.com)
  • There are ten drug master file entries for busulfan. (drugpatentwatch.com)
  • Langman L.J., Danso D., Robert E., Jannetto P.J. (2016) High-Throughput Quantitation of Busulfan in Plasma Using Ultrafast Solid-Phase Extraction Tandem Mass Spectrometry (SPE-MS/MS). In: Garg U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. (springer.com)
  • A vertically integrated pharmaceutical company heavily focused on research & development and in manufacturing drug intermediates, Active Pharmaceutical Ingredients (API) & finished formulations is searching for suppliers of Busulfan and L-Asparaginase injections. (pharmacompass.com)
  • Busulfan with NDC 0409-1112 is a a human prescription drug product labeled by Hospira, Inc.. The generic name of Busulfan is busulfan. (ndclist.com)
  • busulfan is a topic covered in the Davis's Drug Guide . (unboundmedicine.com)
  • Medicine Central , im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/51117/all/busulfan. (unboundmedicine.com)
  • This is not a complete list of busulfan drug interactions. (rxwiki.com)
  • The conditioning drug busulfan is used to ablate host haematopoietic stem cells while leaving the peripheral immune system intact. (bio-protocol.org)
  • 2004). To avoid the perturbation of immune homeostasis caused by irradiation, we turned our attention to the conditioning drug busulfan. (bio-protocol.org)
  • Oral bioavailability of busulfan shows a large interindividual variation. (wikipedia.org)
  • Oral busulfan clearance was associated with GSTA1 (P = .008) but not GSTM1 (P = .57) genotypes. (cdc.gov)
  • However, among the GSTA1 haplotypes (ie, *A*A, *A*B, *B*B), there was significant overlap in the observed oral busulfan clearance and similar rates of achieving the target busulfan exposure. (cdc.gov)
  • These data suggest that personalizing either IV or oral busulfan dosing cannot be simplified on the basis of GSTA1 or GSTM1 genotype. (cdc.gov)
  • Association of Oral Busulfan Clearance with GSTA1 (panel 3A, P=0.008) but not GSTM1 (panel 3B, p=0.57). (cdc.gov)
  • Busulfan belongs to the group of medicines known as alkylating agents. (mayoclinic.org)
  • Some medicines can affect how busulfan works. (limamemorial.org)
  • If you become pregnant while taking busulfan, call your doctor immediately. (medlineplus.gov)
  • If you are a woman, do not use busulfan if you are pregnant. (drugs.com)
  • It is important that you do not get pregnant while being treated with Busulfan. (mims.com)
  • Do not use it if you had an allergic reaction to busulfan, or if you are pregnant. (limamemorial.org)
  • you should know that busulfan may interfere with the normal menstrual cycle (period) in women, may stop sperm production in men, and may cause infertility (difficulty becoming pregnant). (navigatingcare.com)
  • Women should not get pregnant while on busulfan. (rxwiki.com)
  • It is important that you do not get pregnant or father a child while you are taking busulfan. (high-kick.ru)
  • Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. (ac.ir)
  • 13. Tagirov M, Golovan S. The effect of busulfan treatment on endogenous spermatogonial stem cells in immature roosters. (ac.ir)
  • Male mice were received busulfan or irradiation and then fed on the Goshajinkigan-including diet. (nii.ac.jp)
  • Although the damages of spermatogenesis and the testicular immunology after busulfan- or irradiation-treatment are different, Goshajinkigan can completely cure the severe aspermatogenesis after busulfan- or irradiation-treatment in mice. (nii.ac.jp)
  • Journal Article] Male infertility after anticancer treatment and oriental medicine therapy -----Gosha-jinki-gan recovers the intact spermatogenesis in busulfan-induced aspermatogenesis in mice. (nii.ac.jp)
  • Slight decrease in Kitlg mRNA expression has also been observed in mice treated with busulfan , albeit this reduction was not statistically significant In contrast with GDNF and FGF2, KITLG is believed to be involved in SSCs differentiation. (thefreedictionary.com)
  • Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. (myhealthbox.eu)
  • Ameliorative effect of Allium sativum extract on busulfan-induced oxidative stress in mice sperm', Veterinary Research Forum , 9(3), pp. 265-271. (iranjournals.ir)
  • Following euthanasia, blood samples and epididymal sperm were collected.The busulfan-treated group showed significant decreases in sperm qualityparameters, and serum levels of testosterone, LH and FSH was observed in the busulfan-treated mice. (iranjournals.ir)
  • In addition, the TAC levels and antioxidant enzymes activities were reduced and malondialdehyde (MDA) levels were increased in the busulfan-treated mice. (iranjournals.ir)
  • Based on our results, garlic has antioxidant effects against busulfan-induced testicular damages in mice. (iranjournals.ir)
  • The results showed that oxidative stress was increased in busulfan-treated mice during 30 days. (ac.ir)
  • Catalase enzymatic activity decreased significantly in testis of Busulfan-treated mice in comparison with control group. (ac.ir)
  • Improvement in sperm parameters after using gonadotropin releasing hormone analogue in busulfan treated prepubertal mice. (ac.ir)
  • tell your doctor and pharmacist if you are allergic to busulfan, any other medications, or any of the ingredients in busulfan tablets. (medlineplus.gov)
  • Alert your doctor if you have previously taken Busulfan and it did not work. (mims.com)
  • Damage to nerves and nervous system tissues is uncommon with standard busulfan therapy. (encyclopedia.com)
  • Busulfan is eliminated by glutathione S-transferase (GST)-catalyzed conjugation with glutathione (GSH). (aspetjournals.org)
  • Using the candidate gene approach, the authors evaluated whether busulfan clearance was associated with polymorphisms in the genes regulating the predominant metabolizing enzymes involved in busulfan conjugation, specifically glutathione S-transferase (GST) isoenzymes A1 (GSTA1) and M1 (GSTM1). (cdc.gov)
  • You should not use busulfan if you are allergic to it. (drugs.com)
  • Rare reactions to busulfan include: lung problems, cataracts, fatigue, heart problems, low blood pressure, development of another type of cancer or leukemia, enlarged breast tissue (referred to as gynecomastia), and increased uric acid levels (which can lead to kidney problems and gout). (encyclopedia.com)
  • Busulfan is not a cure for leukemia . (drugs.com)
  • In a randomized multicenter study the influence of hydroxyurea versus busulfan on the duration of the chronic phase and on survival of chronic myelogenous leukemia (CML) was determined. (uni-bonn.de)
  • Testing for the Philadelphia chromosome is done to see whether treatment with busulfan is likely to be effective in treating acute myelogenous leukemia. (rxwiki.com)